Abstract: This specification discloses methods, computer-readable media and apparatuses for service execution. In an example, each condition used to construct a rule and an evaluation indicator corresponding to each condition are displayed. Conditions selected by a user from candidate conditions are determined in response to a selection operation of the user. For each candidate condition, a temporary rule is determined based on the candidate condition and the conditions already selected by the user. A degree of reasonableness of each temporary rule is tested based on historical service data, and an evaluation indicator corresponding to each candidate condition is determined based on the degree of reasonableness of each temporary rule and displayed. A target rule is determined in response to a determining operation of the user. A service is executed based on the target rule and service data corresponding to an invocation instruction for invoking the target rule.

Abstract: The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Embodiments of this application provide a configuration method and apparatus. When indicating, by using an RRC connection release message, a terminal to enter an inactive state from a connected state, a network device may include, in the RRC connection release message, a configuration parameter allocated to the terminal in the inactive state. That is, the terminal receives the radio resource control RRC connection release message sent by the network device, where the RRC connection release message includes first information used to indicate a target configuration parameter. In this way, the terminal may enter the inactive state based on the RRC connection release message, and determine a context parameter of the inactive state based on the first information, so that the configuration parameter is properly allocated to the terminal in the inactive state.

Abstract: The present disclosure provides methods of treating chronic graft-versus-host disease (cGVHID) using an antibody that binds to colony stimulating factor 1 (CSF-1R).

Abstract: The disclosure includes compounds of Formula (I) wherein W, R1, R2, R3, R4, R5, R6, m, n, L, and Z1, are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.

Abstract: The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteosome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

Abstract: The present disclosure provides certain 2,3-dihydrobenzo[b]thiophene compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: The present disclosure provides certain indane compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: The present disclosure provides certain alkylidenyl derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

Abstract: The present disclosure provides certain quinazoline derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: The present disclosure provides certain sulfonamido derivatives that are Cyclin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

Abstract: Disclosed herein are processes for preparing certain intermediates useful in the synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or a pharmaceutically acceptable salt thereof.